A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

被引：0
|
作者：
Morten Mau-Sørensen
Christian Dittrich
Rodrigo Dienstmann
Ulrik Lassen
Wilfried Büchler
Holger Martinius
Josep Tabernero
机构：
[1] Rigshospitalet,Department of Oncology, The Finsen Centre
[2] Kaiser Franz Josef-Spital,Ludwig Boltzmann Institute for Applied Cancer Research (LBI
[3] Vall d’Hebron Hospital,ACR VIEnna) – LB Cluster Translational Oncology, Centre for Oncology and Haematology
[4] Neovii Biotech GmbH,Vall d’Hebron Institute of Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Catumaxomab; Bispecific antibody; Phase I; EpCAM; CD3; Solid tumor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1065 / 1073
页数：8
相关论文
共 50 条
  • [1] A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
    Mau-Sorensen, Morten
    Dittrich, Christian
    Dienstmann, Rodrigo
    Lassen, Ulrik
    Buechler, Wilfried
    Martinius, Holger
    Tabernero, Josep
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 1065 - 1073
  • [2] The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
    Suurs, Frans, V
    Lorenczewski, Grit
    Stienen, Sabine
    Friedrich, Matthias
    de Vries, Elisabeth G. E.
    de Groot, Derk Jan A.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1594 - 1601
  • [3] Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study
    Li, Yi-nuo
    Li, Yuan-yuan
    Wang, Shi-xuan
    Ma, Xiang-yi
    CURRENT MEDICAL SCIENCE, 2023, 43 (03) : 539 - 550
  • [4] Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
    Borlak, Juergen
    Laenger, Florian
    Spanel, Reinhard
    Schoendorfer, Georg
    Dittrich, Christian
    ONCOTARGET, 2016, 7 (19) : 28059 - 28074
  • [5] Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study
    Yi-nuo Li
    Yuan-yuan Li
    Shi-xuan Wang
    Xiang-yi Ma
    Current Medical Science, 2023, 43 : 539 - 550
  • [6] Novel conditionally active bispecific EpCAM x CD3 T cell engagers targeting solid tumors.
    Cugnetti, Ana Paula G.
    Liu, Haizhen
    Wang, Jing
    Xing, Charles
    Wheeler, Christina
    Lucas, Matthew
    Chang, Cathy
    Frey, Gerhard
    Boyle, William
    Short, Jay
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Ex vivo treatment of malignant pleural effusions with the bispecific antibody MT110 targeting EPCAM and CD3
    Witthauer, J.
    Schlereth, B.
    Brischwein, K.
    Jauch, K. -W.
    Mayer, B.
    ONKOLOGIE, 2008, 31 : 56 - 56
  • [8] Eradication of gastric carcinoma cells by targeting EpCam and CD3 using bispecific/trifunctional antibodies
    Chaudry, MA
    Sales, K
    Yang, W
    Ruf, P
    Lindhofer, H
    Winslet, M
    BRITISH JOURNAL OF SURGERY, 2005, 92 (10) : 1326 - 1327
  • [9] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study
    Martin Sebastian
    Bernward Passlick
    Hilke Friccius-Quecke
    Michael Jäger
    Horst Lindhofer
    Frank Kanniess
    Rainer Wiewrodt
    Eckhard Thiel
    Roland Buhl
    Alexander Schmittel
    Cancer Immunology, Immunotherapy, 2007, 56 : 1637 - 1644
  • [10] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3):: a phase I study
    Sebastian, Martin
    Passlick, Bernward
    Friccius-Quecke, Hilke
    Jaeger, Michael
    Lindhofer, Horst
    Kanniess, Frank
    Wiewrodt, Rainer
    Thiel, Eckhard
    Buhl, Roland
    Schmittel, Alexander
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (10) : 1637 - 1644
12345